| Amgen's Hopes for Prolia Go Beyond Osteoporosis Therapy The Burrill Report submits: By Michael FitzhughAmgen (AMGN) won an earlier-than-expected FDA approval for denosumab, its treatment for postmenopausal women with osteoporosis at high risk for bone fractures, just days after European regulators approved the drug. Sales of the injectable medicine, to be marketed as Prolia, could generate as much as $942 million in 2011, according to consensus analyst estimates from Bloomberg. Sources polled by EvaluatePharma predicted sales of $5.32 billion by 2016.Complete Story » seekingalpha.com |
Cord Blood America Says U.S., Worldwide Research Shows Umbilical Cord Blood Stem Cells Could Be Crucial in Combating Difficult to Cure Diseases (PR Newswire) Cord Blood America, Inc. , the umbilical cord blood stem cell preservation company focused on bringing the life saving potential of stem cells, a biological insurance policy, to families nationwide and internationally, today said that clinical trials ongoing in the U.S. using umbilical cord blood in the treatment of cerebral palsy, high-risk hematologic cancer, injured spinal cords and Type 1 diabetes provide significant further evidence of the importance of storing umbilical cord blood at the time of birth. us.rd.yahoo.com |
E-Cigarettes Spark New Smoking War A growing group of e-cigarette purveyors are defying the FDA, which contends the nascent nicotine products are drug devices that require pre-market approval and may pose their own health risks. online.wsj.com |
Knee-Device Maker Slams FDA The maker of a knee-repair device said the government's recent move to bar its product was "totally unbelievable" and accused Food and Drug Administration officials of playing politics. online.wsj.com |
New Trial: www.DUETStrial.com - Video Device for Women with Bladder Control Issues May Be an Effective Alternative to Medication and Surgery feedproxy.google.com |